Delilah Hendriks is a senior postdoctoral researcher at the Hubrecht Institute and Benedetta Artegiani is a group leader at the Princess Máxima Center for Pediatric Oncology (PMC). They co-lead their laboratory at the PMC, where they develop and use human organoids for disease modeling.
The research duo met as postdoctoral researchers in Hans Clevers’s laboratory at the Hubrecht Institute. There, Artegiani and Hendriks stumbled upon a mutation that made liver organoids accumulate fat, mimicking non-alcoholic fatty liver disease (NAFLD), a major cause of chronic liver disease worldwide with currently no effective treatment options.1 NAFLD risk associates with factors such as diets high in fat and sugar, genetic predisposition, and genetic lipid disorders. The disease starts with fat accumulation in the liver, a condition called hepatic steatosis, that can progress to an inflammatory stage that results in liver scarring and failure. While in the Clevers laboratory, Artegiani and Hendriks developed several ...
